Evidence map›Paper›PMID 24489760›Full record

ArticlePloS one2014

Telomere length shows no association with BRCA1 and BRCA2 mutation status.

Emma Killick, Malgorzata Tymrakiewicz, Clara Cieza-Borrella, Paula Smith, Deborah J Thompson, Karen A Pooley, Doug F Easton, Elizabeth Bancroft, Elizabeth Page, Daniel Leongamornlert and 3 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. BRCA, infertility, and fertility preservation: a review for counseling.Journal of assisted reproduction and genetics · 2023
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Emma KillickDivision of Medical Oncology, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom ; Oncogentics, Institute of Cancer Research, Surrey, United Kingdom.
Malgorzata TymrakiewiczOncogentics, Institute of Cancer Research, Surrey, United Kingdom.
Clara Cieza-BorrellaUnidad de Medicina Molecular, Universidad de Salamanca, Salamanca, Spain.
Paula SmithCentre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, United Kingdom.
Deborah J ThompsonCentre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, United Kingdom.
Karen A PooleyCentre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, United Kingdom.
Doug F EastonCentre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, United Kingdom.
Elizabeth BancroftCancer Genetics, Royal Marsden Hospital NHS Trust, London, United Kingdom.
Elizabeth PageOncogentics, Institute of Cancer Research, Surrey, United Kingdom.
Daniel LeongamornlertOncogentics, Institute of Cancer Research, Surrey, United Kingdom.
IMPACT collaborators
Zsofia Kote-JaraiOncogentics, Institute of Cancer Research, Surrey, United Kingdom.
Rosalind A EelesOncogentics, Institute of Cancer Research, Surrey, United Kingdom.
Institute of Cancer Research · GBUniversity of Cambridge · GBRoyal Marsden Hospital · GBUniversidad de Salamanca · ES

Funding

UNIVERSITY OF PENNSYLVANIA CAN CTR SUPPORT GRANTP30CA016520 · NCI · UNIVERSITY OF PENNSYLVANIA · PI SHELLEY L BERGER · 1985 to 2026
$222.3M
Cancer Research UK 10118Cancer Research UK 11022Cancer Research UK 13232Cancer Research UK 15007Cancer Research UK 16563NCI NIH HHS P30 CA016520
6 · The paper itself

Abstract

This study aimed to determine whether telomere length (TL) is a marker of cancer risk or genetic status amongst two cohorts of BRCA1 and BRCA2 mutation carriers and controls. The first group was a prospective set of 665 male BRCA1/2 mutation carriers and controls (mean age 53 years), all healthy at time of enrollment and blood donation, 21 of whom have developed prostate cancer whilst on study. The second group consisted of 283 female BRCA1/2 mutation carriers and controls (mean age 48 years), half of whom had been diagnosed with breast cancer prior to enrollment. TL was quantified by qPCR from DNA extracted from peripheral blood lymphocytes. Weighted and unweighted Cox regressions and linear regression analyses were used to assess whether TL was associated with BRCA1/2 mutation status or cancer risk. We found no evidence for association between developing cancer or being a BRCA1 or BRCA2 mutation carrier and telomere length. It is the first study investigating TL in a cohort of genetically predisposed males and although TL and BRCA status was previously studied in females our results don't support the previous finding of association between hereditary breast cancer and shorter TL.

Indexed as

MutationAdultAgedBRCA1 ProteinBRCA2 ProteinBreast NeoplasmsFemaleHeterozygoteHumansMaleMiddle AgedPrognosisProportional Hazards ModelsProstatic NeoplasmsRiskTelomereBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, human

Identifiers

PMID24489760
PMCPMC3906069
OpenAlexW2149547709

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.